We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Agreement to Market Molecular Breast Imaging Technology from Mayo Clinic

By MedImaging International staff writers
Posted on 29 Jan 2010
Gamma Medica-Ideas, Inc. (GMI; Northridge, CA, USA), a developer of digital molecular imaging systems, has signed an exclusive license and commercialization agreement with the Mayo Clinic (Rochester, MN, USA), to further develop and commercialize a suite of technologies invented by a team of Mayo physicians and scientists, headed by Michael O'Connor, Ph.D.

The company aims to utilize the licensed technology in conjunction with its Lumagem molecular breast imaging system to improve the diagnosis of cancers in women with dense breasts. An estimated 30% of women have dense breast tissue, which can impede diagnosis of abnormalities. Existing mammography and other screening techniques are at times either insufficient or very expensive. Molecular breast imaging, however, promises to be a cost-effective solution for these women.

Dr. Bradley Patt, CEO of GMI said, " We are extremely pleased that Dr. O'Connor and his team at Mayo have chosen GMI to bring their important technology to market. The underlying reason for the controversy in mammography is the fact that mammography has underserved groups of women such as the 40-50 year old age group, where higher breast density has rendered mammography much less effective. GMI's LumaGEM system, now enhanced with Mayo's technologies, will be a highly effective solution for such cases. The Mayo technologies, which have been under development and evaluation for the last seven years, enable this procedure to be performed at a radiation dose comparable to a mammogram.”

The range of technologies invented by Mayo Clinic enhance the existing capabilities of GMI's LumaGEM dual-headed imaging system through special image processing software algorithms and collimator and detector optimization techniques. The license also includes methods and devices developed at Mayo for combining next generation X-ray tomosynthesis techniques with molecular imaging of the breast. In initial clinical studies, the Mayo algorithms licensed to GMI yield better images at lower dose.

Funding from internal sources at Mayo, GMI, and the U.S. National Cancer Institute (Bethesda, MD, USA) has been instrumental in moving the technology forward. Under an International Review Board (IRB)-approved screening study, the technology is already showing promising results with just one-third of the standard dose of Tc-99m Sestamibi typically utilized in the procedure.

According to Dr. O'Connor, "Mayo is looking forward to the collaboration with GMI as we work together to bring this advanced technology to the health care industry. We have used GMI's Lumagem technology combined with our inventions to successfully perform close to 2000 patient studies at Mayo over the past four years. We believe that the combination of GMI's detector technology and the algorithms and techniques developed at Mayo, will enable us to achieve a significant reduction in the radiation dose required for molecular breast imaging, and increase the diagnostic utility of this technique.”

"Over the past few years the need for secondary imaging in breast cancer diagnosis has become obvious. Until now dedicated breast MRI [magnetic resonance imaging] has been useful in helping fill the void, and the number of MRI secondary breast imaging scans has quickly grown to almost one million per year,” commented Dr. Patt. "GMI's LumaGEM product in conjunction with the Mayo technology offers accuracy rivaling MRI, with even better specificity and at a fraction of the cost. We are very excited about the possibility of utilizing this technology to deliver improved quality of care in women's health at a lower cost to the healthcare system.”

Mayo Clinic has one of the most highly evolved intellectual property and technology commercialization efforts in academic medicine. The Office of Intellectual Property at Mayo Clinic serves as a bridge between discoveries and the marketplace.

Gamma Medica-Ideas designs, builds, and services imaging systems based on novel technologies to improve patient health through early diagnosis of disease, improved patient treatment, and by enabling new drug discovery.

Related Links:
Gamma Medica-Ideas
Mayo Clinic

Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
New
Mammography System (Analog)
MAM VENUS
Computed Tomography System
Aquilion ONE / INSIGHT Edition
New
Post-Processing Imaging System
DynaCAD Prostate

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.